Clinical Trials Logo

Clinical Trial Summary

This Phase IIIb, multicenter study will assess the safety of atezolizumab as second- to fourth-line treatment for participants with locally advanced or metastatic urothelial or non-urothelial cancer of the urinary tract in addition to evaluate the efficacy of atezolizumab and potential tumor biomarkers associated with atezolizumab.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02928406
Study type Interventional
Source Hoffmann-La Roche
Contact
Status Completed
Phase Phase 3
Start date November 30, 2016
Completion date December 12, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05544552 - Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations Phase 1/Phase 2
Recruiting NCT02379429 - Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue
Recruiting NCT05038657 - Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC). Phase 2
Completed NCT04430842 - Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S Phase 1
Recruiting NCT04718948 - Multimodal Spectroscopy to Detect Urothelial Cancer in Urine
Completed NCT02006667 - A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer Phase 2
Terminated NCT02013765 - A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer Phase 2
Completed NCT03410641 - Long-term Cancer Risk in the Randomised Oslo Diet and Antismoking Study N/A
Completed NCT03013920 - CLE Characteristics of Upper Urinary Tract Urothelial Carcinoma